^(125)Ⅰ粒子植入联合支气管动脉灌注治疗中晚期肺癌的临床应用

The clinical application of ^(125)Ⅰ seeds implantation together with bronchial arterial infusion chemotherapy for the treatment of advanced lung cancer

目的评估125I粒子植入联合支气管动脉灌注化疗治疗中晚期肺癌的临床疗效。方法回顾性分析行125I粒子植入联合支气管动脉灌注化疗的中晚期肺癌患者30例的疗效和不良反应,每例粒子植入数为3～70粒(6711型,0.7mCi/粒)。所有患者分别在粒子植入术前7d、术后30、60d进行支气管动脉灌注化疗,根据RECIST标准判定疗效。结果所有患者共40个病灶均成功植入125I粒子,未发生手术相关严重并发症,术后随访2～24个月。本组患者2年生存率为86.6%(26/30),术后4个月评估疗效:CR26例,PR10例,NC2例,PD2例,总有效率为90%。结论 125I植入联合支气管动脉灌注化疗治疗中晚期肺癌疗效明显,是一种治疗中晚期肺癌安全,有效的方法之一。

Objective To assess the clinical value of 125↑Ⅰ seeds implantation combined with the bronchial arterial infusion chemotherapy in treating advanced lung cancer. Methods 125↑Ⅰ seeds implantation combined with the bronchial arterial infusion chemotherapy was performed in 30 patients with advanced lung cancer. About 3 -70 seeds of 125↑I （6711 type,0.7 mCi / seed） were delivered in each patient. In all patients bronchial arterial infusion chemotherapy was carried out at the time of 7 days before the implantation and 30 and 60 days after the implantation. The results and complications were observed. The clinical data were retrospectively analyzed. The therapeutic efficacy was evaluated according to RECIST standards. Results A total of 40 lesions were detected in all 30 patients and 125↑I seeds were successfully embedded in all lesions. No procedure-related complications occurred. All patients were followed up for 2 -24 months. The two-year survival rate was 86.6% （26 / 30）. Therapeutic evaluation made at four months after the treatment showed that CR,PR,NC and PD was seen in 26,10,2 and 2 lesions respectively,with a total effective rate of 90%. Conclusion 125↑Ⅰ seeds implantation combined with the bronchial arterial infusion chemotherapy is a safe and effective therapy for advanced lung cancer with excellent clinical results.